# A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood

> **NCT04445090** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 68 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1569912
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04445090
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-21
- **Primary completion:** 2021-09-10
- **Final completion:** 2021-09-10
- **Target enrollment:** 68 (ACTUAL)
- **Why stopped:** Identification of potential mutagenic metabolite in human plasma
- **Last updated:** 2021-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04445090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04445090, "A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04445090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*